Drugs for Neglected Diseases Initiative (DNDi)
Despite major advances in drug development in recent decades, essential medicines to treat many diseases that affect the world’s poor are either too expensive, no longer produced, highly toxic, or ineffective. Recognising these issues from its field experience, MSF committed its 1999 Nobel Peace Prize funds to develop an alternative model for the research and development (R&D) of new drugs for neglected diseases.
As a result, in 2003, seven organisations from around the world joined forces to establish DNDi: five public sector institutions – the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia and France’s Pasteur Institute; one humanitarian organisation, Médecins sans Frontières (MSF); and one international research organisation, the UNDP/World Bank/WHO’s Special Programme for Research and Training in Tropical Diseases (TDR), which acts as a permanent observer to the initiative.
Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for malaria, visceral leishmaniasis (VL), sleeping sickness (human African trypanosomiasis, HAT), and Chagas disease.
For more information, Click here.